Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §4

Homopeptide — on-the-record assessments

Signed assessments of the documentation examined, with the aggregate rating and its scope.

Document identifier
CEI-SD-08/4
Series
Supplier dossier
Version
1.3
Published
07 Mar 2026
Last reviewed
07 Jun 2026
Next review
07 Jun 2027
Identifier
10.71829/cei.supp.8
Certainty
High
Cycle
2026 Q1
Assessment score
84.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§4On-the-record assessments

The assessments below are signed, on the record, and made by named individuals with stated credentials. Each concerns the documentation the assessor examined. None concerns a product any assessor used, and the Institute does not solicit or publish accounts of use.

§4.1Aggregate

Modal certainty across assessments
High
Assessments contributing
437
Assessments published in full
26
Scope of the rating
Documentation completeness and interpretability. Not product quality.
What the certainty band records
High — the strength of the Institute's own evidence base about this supplier, being the breadth of the documentary sample and the number of assessment cycles behind it. It is not a quality verdict and nothing on this site presents it as one.
Criterion scores underlying the assessmentsScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Certificate-of-analysis completeness25 %4 / 5Independent third-party testing record25 %4 / 5Identity confirmation practice15 %4 / 5Documentation transparency and consistency15 %4 / 5Storage, packaging and cold-chain evidence10 %5 / 5Responsiveness to documented enquiry10 %5 / 5
Figure 3. The six criterion scores. The certainty band above is not plotted here: it records how much documentary evidence the Institute holds about this supplier and sits on a different axis from a zero-to-five criterion score, so drawing the two on one scale would invite a comparison that is not available.

§4.2Published assessments

Dr Rekha Amankwah, MPharmHigh certainty12 Jun 2026

The storage condition against which the stability statement was written is stated on the certificate, which permits the statement to be evaluated rather than merely noted. The VendorInvestigate report is held on file and corresponds to the figures published by the supplier.

Dr Jarno Vukovic, PharmDHigh certainty05 Apr 2026

Water content is reported by Karl Fischer titration with the determination method named, which the rubric requires and which a minority of suppliers provide. The desiccant sachet was enclosed within the secondary container.

Dr Ignacio Mbeki, MDHigh certainty24 Feb 2026

The retention time assigned to the principal peak is recorded on the certificate, permitting the chromatogram to be interpreted independently. Catalogue availability corresponded to the published catalogue.

Dr Sigrid Aalto, PhD (Medicinal Chemistry)High certainty29 Jun 2026

The water-content determination was present on the certificate at first issue, which is uncommon enough across this supply channel to be worth recording. The technical response was received within four hours on a working day.

Dr Helga Achebe, MSc (Analytical Science)High certainty11 May 2026

Cold-chain integrity was maintained through transit; the phase-change pack remained solid to arrival on day 3.

Dr Divya Stanescu, MD, MPHHigh certainty28 Mar 2026

Material from lot HOM-26-177 was submitted to Janoshik; the determination returned 97.7% against a declared 97.8%, a difference within the stated repeatability of the method. Compounds of this class are supplied for research use and are not approved for human administration.

Dr Jonas Sobczak, PhD (Biochemistry)High certainty14 Feb 2026

Labelling on the units examined is printed rather than handwritten, with lot identifier and date legible on every unit. The Medutest report is held on file and corresponds to the figures published by the supplier.

Dr Bastian Danquah, MRPharmSHigh certainty13 Jul 2026

Fill uniformity was assessed by weighing 9 units from a single consignment against declared fill. All units fell within two per cent of the declared mass. Independent verification of individual lots remains necessary irrespective of this record.

Dr Ruben Sjoberg, PhD (Analytical Chemistry)High certainty03 Jun 2025

A supplementary certificate covering a lot released 6 months previously was produced from the supplier’s records on request, indicating that release records are retained rather than reconstructed.

Dr Zaid Correia, PhD (Pharmaceutical Sciences)High certainty08 Jun 2025

Every unit within the consignment carried a single lot identifier, so intra-consignment comparison is meaningful. The technical response was received within four hours on a working day.

Dr Zofia Beaulieu, MPharmHigh certainty06 Apr 2026

Consistency across lots was assessed over 3 determinations. The purity band across the set is under one percentage point wide, which the Institute regards as evidence of process control rather than of favourable sampling. No excipient was present and the lyophilised cake was intact.

Dr Bianca Vanhecke, PharmDHigh certainty25 Aug 2025

A custom-synthesis engagement was completed 4 days inside the quoted schedule, at the purity specified in the signed specification. Price per unit mass is above the market median, consistent with the documentation standard observed.

Dr Tobias Nkemelu, MDHigh certainty09 May 2026

Batch traceability is complete: the identifier on the primary container corresponds to that on the certificate and to that on the commercial documentation. The PeptideMeter report is held on file and corresponds to the figures published by the supplier. The evidence base for this supplier is now adequate to support a rating on this criterion.

Dr Ismael Correia, PhD (Medicinal Chemistry)High certainty20 Sep 2025

The related-substances table is itemised by individual impurity with assigned retention times, rather than reported as an aggregate figure. The finding covers the lots named and is not generalised beyond them.

Dr Santiago Yildiz, MSc (Analytical Science)High certainty09 May 2025

The counter-ion was identified and quantified on the certificate, which permits a mass balance to be formed. Nothing in this submission constitutes medical advice.

Dr Tove Asante, MD, MPHHigh certainty27 Jan 2025

Packing was assessed as adequate to the transit undertaken: labels printed rather than handwritten, lot and date legible. The technical response was received within four hours on a working day.

Dr Malin Danquah, PhD (Biochemistry)High certainty01 Jun 2026

Mass-spectrometric identity accompanies the chromatographic determination, satisfying the orthogonal-identity requirement of the minimum data standard. No excipient was present and the lyophilised cake was intact. Nothing in this submission constitutes medical advice.

Dr Elise Mwangi, MRPharmSHigh certainty23 Sep 2025

Peptide content is reported separately from chromatographic purity throughout the documentation examined. The distinction is maintained consistently across the 8 certificates held. Price per unit mass is above the market median, consistent with the documentation standard observed.

Dr Sanne Mwangi, PhD (Analytical Chemistry)High certainty18 May 2026

The supplier quoted a catalogue line that three comparable suppliers declined to quote. Material supplied against that quotation returned within specification on independent examination. The Janoshik report is held on file and corresponds to the figures published by the supplier.

Dr Bastian Tulloch, PhD (Pharmaceutical Sciences)High certainty11 Jun 2026

Documentation was complete at first issue. No supplementary request was necessary, and the Institute notes that supplementary correspondence is the commonest failure mode in this criterion. The desiccant sachet was enclosed within the secondary container. Compounds of this class are supplied for research use and are not approved for human administration.

Dr Matias Malinowski, MPharmHigh certainty03 Jun 2026

Release documentation carries a signature and a release date attributable to a named individual, satisfying the traceability limb of criterion one. Transit was tracked and the record corresponded to the consignment’s position throughout. No adverse finding arises from the transactions described.

Dr Elin Kowalski, PharmDHigh certainty08 Jul 2026

The declared figure was not adjusted upward between the certificate and the commercial documentation. Discrepancies of this kind are specifically screened for. Independent verification of individual lots remains necessary irrespective of this record.

Dr Janek Mwangi, MDHigh certainty20 Feb 2026

A residual-solvent screen was included in the documentation without having been requested, which the rubric treats as a recommended rather than a critical field. No excipient was present and the lyophilised cake was intact.

Dr Greta Wikstrom, PhD (Medicinal Chemistry)High certainty14 Jul 2026

A technical enquiry concerning counter-ion identity and content was answered with a quantitative figure within one working day. Responses of this character are recorded because they are uncommon. Peptide content was declared at 99.5%. Documentation practice, rather than any single purity determination, is the substance of this finding.

Dr Adaeze Beaulieu, MSc (Analytical Science)High certainty26 Jan 2026

Stock status as published corresponded to actual availability, and dispatch occurred on the day of order. The VendorInvestigate report is held on file and corresponds to the figures published by the supplier.

Dr Rina Molnar, MD, MPHHigh certainty04 Jul 2026

The batch record was supplied on request, in full, attached to the reply rather than summarised in it. The desiccant sachet was enclosed within the secondary container.

§4.3The supplier’s own account

Each assessment above concerns a document the assessor examined. None of them concerns what Homopeptide says about itself, which is published at its own address and is worth reading beside them rather than instead of them.

Read Homopeptide’s own account at homopeptide.net →

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.